Allogene Therapeutics, Inc. Announces Departure of Timothy MooreOn January 23, 2025, Allogene Therapeutics, Inc. (NASDAQ: ALLO) revealed in an 8-K filing that Timothy Moore, the Company’s incumbent executive, would be concluding his tenure with the o

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Allogene Therapeutics’s 8K filing here.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).